<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>ANTI-MYCOTICS:</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\14.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>ANTI-MYCOTICS: <a name='13:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<p>
→ <b>Amphotericin B</b><br>
<ul style='padding-left: 30pt'>
<li>first efficacious antifugnal drug available for systemic use</li>
<li>quite toxic</li>
</ul>
</p>

<p>
→ then introduction of "nontoxic" <b>azoles</b>.<br>
<ul style='padding-left: 30pt'>
<li>oral and parenteral formulation</li>
</ul>
</p>

<p>
→ and the <b>echinocandins</b><br>
<ul style='padding-left: 30pt'>
<li>parenteral admin.</li>
</ul>
</p>

<p>
→ Categories:<br>
<ul style='padding-left: 30pt'>
<li>systemic drugs ( oral and parenteral ) for systemic infenctions</li>
<li>oral systemic drugs for mucocutaneous infenctions</li>
<li>topical drugs for mucocutaneous infenctions.</li>
</ul>
</p>

<h3>→ Amphotericin B</h3>

<p>
→ A and B are antifungal antibiotics produced by Streptomyces nodosus.<br>
<ul style='padding-left: 30pt'>
<li>Amphotericin B is not in clinical use.</li>
</ul>
</p>

<p>
→ B = amphoteric polyene macrolide<br>
<ul style='padding-left: 30pt'>
<li>[ polyene = containing many double bonds ] - [ macrolides = containing a large lactone ring of 12 or more atoms ]</li>
<li>insoluble in water =&gt; collodial suspensions and sodium desocycholate for intravenous injections.</li>
</ul>
→ poorly absorbed from the GIT<br>
<ul style='padding-left: 30pt'>
<li>oral admin. is effective only on fungu within the lumen of the tract/</li>
</ul>
→90% bound by seroum proteins.<br>
→ excreted slowly in the urine over a period of several days.<br>
→ serum half-life 15 days.
</p>

<br>

<p>
<b>Mechanism of Action &amp; Resistance:</b>
</p>

<p>
→ selective , fungicidal effect<br>
<ul>
<li>eploits the differecne in lipid composition of fungal and mammalian cell membrances.</li>
</ul>
</p>

<p>
→ <b>Ergosterol </b>(cell membranes sterol)<br>
<ul style='padding-left: 30pt'>
<li>amphotericin B is bind to ergosterol and alerts permability of the cell by forming amphotericin B associated pores in the cell membrane.</li>
</ul>
<img src="./Pharmacology/pasted_image.png"><br>
→ avidly combine with lipids (ergosterol) along the double bond-rich side of its structure and associatse with water molecules along the hydroxy-rich side.<br>
<ul style='padding-left: 30pt'>
<li>amphipathetic characterists facilitates pore formation[lipophilic portion around the outside ]-[hydrophilic regions lining the inside]</li>
</ul>
→ pores allows:<br>
<ul style='padding-left: 30pt'>
<li>allows the leakgage of intracellular ions and macromolecule → leadin to cell deaths.</li>
</ul>
→ Resistance to amphotericin B occurs if ergosterol binding is impaired<br>
<ul style='padding-left: 30pt'>
<li>by decreasing the membrane concentrantion of ergosterol</li>
<li>modifying the sterol target molecule to reduce its affinity for the drug</li>
</ul>
</p>

<br>

<p>
<b>Antifungal Activity &amp; Clinical Uses:</b><br>
→ the broadest spectrum of action.<br>
→ activity against significant yeasts<br>
<ul style='padding-left: 30pt'>
<li>Candida albicans </li>
<li>Cryptococcus neoformans</li>
</ul>
→ endemic mycoses <br>
<ul style='padding-left: 30pt'>
<li>Histoplasma capsulatum</li>
<li>Blastomyces dermatitis</li>
<li>Coccidiodes immitis</li>
</ul>
→ Resistance by<br>
<ul style='padding-left: 30pt'>
<li>Candida lusitaniae </li>
<li>Pseudallescheria boydii</li>
</ul>
</p>

<br>

<p>
→ rapidly reduce fugnal burden and then replaced with some newer azole.<br>
<ul style='padding-left: 30pt'>
<li>severe fungal pneumonia,severe cryptococcal menigitis</li>
</ul>
</p>

<p>
→ Local or Topical admin.<br>
<ul style='padding-left: 30pt'>
<li>mycotic corneal ulcers</li>
<li>keratitis</li>
</ul>
</p>

<p>
<b>Adverse effects:</b><br>
→ two types of reactions<br>
<ul style='padding-left: 30pt'>
<li>immediate  ( related to the infusion of the drug)</li>
<li>more slowly</li>
</ul>
<div style='padding-left: 60pt'>
a.Infusion-Related Toxicity
</div>
→ fever, chills, muscle spams, vomiting , headache , hypotension<br>
<div style='padding-left: 60pt'>
b.Cumulative Toxicity
</div>
→ renal damage<br>
→ abnormalities of liver function occasionally seen (as in a varying form of anemia)
</p>

<h1>Flucytosine</h1>

<p>
→ potent antifugnal agents<br>
→ water-soluble pyrimidine analog related to the chemotherapeutic agent 5-flurouracil (5-FU)<br>
→ narrowest spectrum than that of amphotericin B
</p>

<p>
→ only in an oral formulation<br>
→ dosage : 100-150 mg/kg/d<br>
→ absorbed (&gt;90%)<br>
→ poorly protein bound<br>
→ glomerular filtration with a half-life 3-4 hours.<br>
→ levels rise rapidly with renal impairment and can lead to toxicity
</p>

<br>

<p>
<b>Mechansm of Action &amp; Resistance:</b><br>
→ taken up by fungal cells via the enzyme cytosine permase<br>
<ul style='padding-left: 30pt'>
<li>converted intracellularly first to 5-FU</li>
<li>and then to 5-flurodeoxyuridine monophosphate and fluorouidine triphosphate</li>
</ul>
→ which inhibits DNA and RNA synthesis.<br>
→ humman cells are unable to convert the parent drug to its active metabolites, resulting in selective toxicity<br>
→ synergy with amphotericin B<br>
<ul style='padding-left: 30pt'>
<li>and azole</li>
</ul>
→ Resistance mediated through altered metabolism of flucytosine<br>
<ul style='padding-left: 30pt'>
<li>develops rapidly in the course of flucytosine monotherapy.</li>
</ul>
</p>

<br>

<p>
<b>Clinical Uses &amp; Adverse Effects:</b><br>
→ spectrum of activity restricted to<br>
<ul style='padding-left: 30pt'>
<li>C.neoformans </li>
<li>some Candidass species</li>
<li>dematiaceous molds that cause chromoblastomycosis.</li>
</ul>
→ is not used as a signle agent<br>
<ul style='padding-left: 30pt'>
<li>with amphotericin B for cryptococcal menigitis</li>
<li>itraconazole for chromoblastomycosis.</li>
</ul>
→ bone marrow toxicity with anemia, leukopenia , thrombocytopenia 
</p>

<h1>AZOLES</h1>

<p>
<b>Chemistry&amp;Kinetics</b>
</p>

<p>
→ synthetic compounds that can be classified:<br>
<ul style='padding-left: 30pt'>
<li>imidazoles ⇒ [Ketoconazole , Miconazole , Clotrimazole ] → the latter two drugs are used only in TOPICAL THERAPY</li>
<li>triazoles ⇒ [Itraconazole , Fluconazole, Voriconazole, Posaconazole]</li>
</ul>
→ according to the number of nitrogen atoms in the five-membered azole ring<br>
<img src="./Pharmacology/pasted_image001.png"><br>
→ pharmacology of each is unique.
</p>

<br>

<p>
<b>Mechanisms of Actions &amp; Resistance:</b><br>
→ reduction of ergosterol synthesis by inhibition of fungal cytochrome P450 enzymes.<br>
→ greater affinity for fugnal than for human cytochrome <br>
→ Imidazoles lesser degree of selectivity than the triazoles<br>
<ul style='padding-left: 30pt'>
<li>higher incidence of drug interactions and adverse effects.</li>
</ul>
</p>

<br>

<p>
<b>Clinical Uses,Adverse Effects  &amp; Drug Interaction:</b><br>
→ spectume is broad <br>
<ul style='padding-left: 30pt'>
<li>Candida,C.neoformans</li>
</ul>
→ the endemic mycoses: <br>
<ul style='padding-left: 30pt'>
<li>blastomycosis, coccidiooidomycosis, histoplasmosis </li>
</ul>
→ dermatophytes<br>
→ in the case of itraconazole,voriconazole → Aspergillus infenctions.<br>
→ also useful in the treatment of amphoterecin-recistance organism such as P.boydii.<br>
→ relative non toxic [  minor GIT upsets ]
</p>

<h2>Ketoconazole:</h2>

<p>
→ first oral azole.<br>
→ distinguished by triazoles by its greater propensity to inhibit mamalian cytochrome P450 enyzmes.<br>
<ul>
<li>less effective for fungal P450.</li>
</ul>
</p>

<br>

<h2>Itraconazole:</h2>

<p>
→ oral and intravenous fomrulation<br>
<ul style='padding-left: 30pt'>
<li>dosage : 100-400 mg/d</li>
</ul>
→ absorption ↑ — food — low gastric pH<br>
→ lipid-soluble azoles → interacts with hepatic microsomal enzymes ( lesser degree than ketoconazole)<br>
→ ↓ bioavailability of itraconazole when taken with rifamycins.<br>
<ul style='padding-left: 30pt'>
<li>( rifampin , rifabutin , rifapentine )</li>
</ul>
→ porent antifugnal activity <br>
→ oral liquid, intravenous preparations ( with cyclodextran as a carrier molecule to ↑ solubility  and bioavailability )<br>
→ poorly penatrates into the cerebrospinal fluid.<br>
→ Histoplasma,Blastomyces,Sporthrix<br>
→ used extensively in the treatment of dermataophytoses onychomycosis.
</p>

<br>

<h2>Fluconazole:</h2>

<p>
→ high degree of water solublity and good cerebrospinal fluid penatration.<br>
→ oral bioavailability is high <br>
→ least effect of all the azoles on hepatic microsomal enzymes<br>
→ widest therapeutic index of the azoles<br>
<ul style='padding-left: 30pt'>
<li>permiting more aggresive dosing in a variety of fungal infecntios.</li>
</ul>
→ oral and intravenous formulation <br>
<ul style='padding-left: 30pt'>
<li>dosage : 100-800 mg/d.</li>
</ul>
→ treatment and secondary prophylaxis of cryptococcal meningitis.<br>
→ treatment of mucocutaneous candidiasis.<br>
→ profilactic use of fluconazole <br>
<ul style='padding-left: 30pt'>
<li>↓ fungal disease in bone marrow transplant recipients and aids patients</li>
<li>emergence of fluconazole-resistance fungi has raised concerns about this indication.</li>
</ul>
</p>

<br>

<h2>Voriconazole:</h2>

<p>
→ intravenous and oral formulation<br>
→ 400 mg/d<br>
→ well absorbed orally ( bioavailability exceeding 90%)<br>
→ less protein binding than itracoanzole.<br>
→ hepatic metabolism<br>
→ relevant inhibitor of mamalian CYP3A4 <br>
<ul style='padding-left: 30pt'>
<li>doso of medications  should be reducted when voriconazole is s tarted.</li>
</ul>
— cyclosporines — tacromilus — HMG-Coa reductase inhibitors<br>
→ rash and elevated hepatic enzymes<br>
<ul style='padding-left: 30pt'>
<li>visual distrubances</li>
<li>photosensitivity demratitis</li>
</ul>
→ similar spectrum of action with itraconazole<br>
→ less toxic than amphotericin B<br>
→ choice of treatment for invasive aspergillosis.
</p>

<h2>Posaconazole:</h2>

<p>
→ newst  "triazole"<br>
→ only in liquid oral formulation<br>
<ul style='padding-left: 30pt'>
<li>dosage : 800 mg/d , devided into two or three doses</li>
</ul>
→ absorption improved when taken with meals high in fats.<br>
→ rapidly distributed to the tissues → high tissue levels but low blood levels<br>
→ CYP3A4 substrates such as : ( tracrolimus , cyclosporine )<br>
→ broadest spectrum member of azole<br>
→ Candida &amp; Aspergillus<br>
→ mucormycosis<br>
→ salvage therapy in invasive aspergillosis <br>
→ prophylaxis of fugnal infections during induction chemotherapy for leukemia.
</p>

<h1>Echinocandids</h1>

<p>
<b>Chemistry and Kinetics :</b><br>
→ newest class of anti-fugnal agents<br>
→ large c yclic peptides linked to a long-chain fatty acids.<br>
→ Caspfungin, micafugin , anidulafungin<br>
→ Candida and Aspergillus <br>
→ Only in intravenous formulations<br>
→ <b>Caspofungin </b><br>
<ul style='padding-left: 30pt'>
<li>single dose of 70mg followed by daily dose of 50mg</li>
<li>water-soluble &amp; highly-protein bound.</li>
<li>half-life is 9-11 hours</li>
<li>excreted by the kidneys and GIT</li>
<li>dosa adjustment required in case of hepatic impairment.</li>
</ul>
→ Micafungin <br>
<ul style='padding-left: 30pt'>
<li>half-lifef 11-15hours</li>
<li>dose of 150 mg/d → esophageal candidiasis</li>
<li>dose of 100 mg/d → candidemia</li>
<li>dose of 50  m g/d   → prophylaxis of fungal infenction</li>
</ul>
</p>

<p>
→ Anidulafungin <br>
<ul style='padding-left: 30pt'>
<li>half-life 24-48 hours → esophageal candidiasis </li>
<li>single dose of 100 mg/d and 50 mg/d for 14 days.</li>
</ul>
→ candidemia : loading dosage of 200 mg → 100 mg thereafter for 14 days.
</p>

<p>
<b>Mechanism of action:</b><br>
→ act at the level of the fungal cell wall by inhibiting the synthesis of β(1-3)-glucan<br>
<ul style='padding-left: 30pt'>
<li>results in disruption of the f ungal cell wall and cell death</li>
</ul>
</p>

<p>
<b>Clinic Uses &amp; Adverse Effects:</b><br>
→ Capsofungin <br>
<ul style='padding-left: 30pt'>
<li>disseminated and mucocutaneus candidal infenction</li>
<li>empiric antifugnal therapy during febrile neutropenia</li>
</ul>
</p>

<p>
→ Micafungin<br>
<ul style='padding-left: 30pt'>
<li>mucocutaneus candidiasis</li>
<li>candidemia</li>
<li>prophylaxis of candidal infenctions in bone marrow transplant patients.</li>
<li>increase levels of nifedipine, cyclosporine , sirolimus</li>
</ul>
</p>

<p>
→ Anidulafungin <br>
<ul style='padding-left: 30pt'>
<li>esophageal candidiasis </li>
<li>invasive candidiasis , including ( candidemia )</li>
<li>does not shown any significant drug interanction.</li>
</ul>
</p>

<p>
→ Echinocandin agents:<br>
<ul style='padding-left: 30pt'>
<li>extremely well tolarated</li>
<li>minor GIT side effects and flushing.</li>
<li>elavated liver enzymes when it is combined with cyclosporine.</li>
</ul>
</p>

<br>
<br>

<h1>ORAL SYSTEMIC ANTIFUNGAL DRUGS FOR MUCOCUTANEOUS INFENCTIONS:</h1>

<br>

<h1>Griseofulvin</h1>

<br>

<p>
→ very insoluble fungiastatic drug from species of penicillium.<br>
→ systemic treatment of dermatophytosis.<br>
→ admin. in a microcrystalline form at a dosage of 1g/d.<br>
→ absortption is improved when it is given with fatty foods.
</p>

<p>
→ moa at cellular level is unclear<br>
<ul style='padding-left: 30pt'>
<li>deposited in newly forming skin where it binds to keratin (protecting the sking from new infenction)</li>
<li>admin. 2-6 week for skin/hair infenctions (allow replacement of infected keratin by the resisatant structures)</li>
<li>Nail infenctions → therapy for monhts</li>
</ul>
→ adverse effects include:<br>
<ul style='padding-left: 30pt'>
<li>allergic syndrome like ( serum sickness , hepatitits )</li>
<li>drug interanctions with — warfarin —  phenobarbital</li>
</ul>
→ Griseofulvin replaced by newer antifugnal medications such as itraconazole &amp; terbinafine.
</p>

<h1>Terbinafine</h1>

<br>

<p>
→ synthetic allylamine in ORAL formulation<br>
<ul style='padding-left: 30pt'>
<li>dosage : 250 mg/d → dermatophytoses , especially onychomycosis.</li>
<li>keratophillic medication &amp; fungicidical</li>
<li>interefers with ergosterol biosynthesis </li>
</ul>
→ rather than inhibit the P450 enzyme system <br>
<ul style='padding-left: 30pt'>
<li>inhibiting enzyme " squalene epoxidase "</li>
<li>which leads to mulation of the sterol squalene which is toxic to organism.</li>
</ul>
→ one tablet given daily for 12 weeks<br>
→ GIT upset &amp; headache
</p>

<h1>TOPICAL ANTIFUGNAL THERAPY</h1>

<br>

<h1>Nystatin</h1>

<br>

<p>
→ polyene macrolide much like amphotericin B<br>
<ul>
<li>too toxic for parenteral admin and is only used topically.</li>
</ul>
→ available in <br>
<ul style='padding-left: 30pt'>
<li>creams</li>
<li>oitments</li>
<li>suppositories</li>
<li>and other for mucus membranes &amp; skin</li>
</ul>
→ not absorbed to a significant degree from skin → little toxicity<br>
→ oral admin. is often limited due to bad taste<br>
→ Candida sp<br>
<ul style='padding-left: 30pt'>
<li>suppression of local candidal infenctions</li>
<li>oropharyngeal thrush</li>
<li>vaginal candidiasis</li>
<li>intertriginous candidal infenctions</li>
</ul>
</p>

<h1>TOPICAL AZOLES DERIVATIVES</h1>

<p>
→ Clotrimazole  &amp;  Miconazole &amp; Econazole &amp; Oxiconazole &amp; Ketokonazole etc<br>
<ul>
<li>cream/lotion/vaginal cream or supp/tablets</li>
</ul>
→ suppositories<br>
<ul style='padding-left: 30pt'>
<li>vulvovaginal candidiasis</li>
</ul>
→ oral clotrimaole<br>
<ul style='padding-left: 30pt'>
<li>oral thrush</li>
<li>pleasant-tasting alternative to nystatin</li>
</ul>
→ cream form <br>
<ul style='padding-left: 30pt'>
<li>dermatmophytic infenctions</li>
<li>tinea corporis</li>
<li>tinea pedis</li>
<li>tinea cruris</li>
</ul>
→ absorbtion is negligible and adverse effects are rare.<br>
→ topical and shampoo forms of ketoconazole are also available<br>
<ul style='padding-left: 30pt'>
<li>seborrheic dermatitits and pityriasis versicolor</li>
</ul>
</p>

<h1>Ciclopirox olamin</h1>

<p>
→ synthetic broad-spectrum antimycotic agent<br>
<ul style='padding-left: 30pt'>
<li>inhibitory acticity against → dermatophytes , candida species , P.orbiculare</li>
</ul>
→ inhibit the uptake of precursosrs of macromolecular synthesis → [fugnal cell membrane]
</p>

<p>
→ 1% cream and lotions (Loprox) <br>
<ul style='padding-left: 30pt'>
<li>dermatomycosis</li>
<li>candidiasis </li>
<li>tinea versicolor</li>
</ul>
→ 8% ciclopirox olamine (Penlac nail lacquer)<br>
<ul style='padding-left: 30pt'>
<li>mild to moderate onychomycosis of fingernails and toeanails.</li>
</ul>
</p>

<h1>TOPICAL ALLYLAMINES</h1>

<p>
→ Terbinafine and naftitine<br>
<ul>
<li>highly active against dermatophytes</li>
<li>less active against yeast</li>
</ul>
→ selective inhibition of squalene epoxidase ( key enzyme in ergosterol synthesis )<br>
→ 1% topical creams<br>
<ul style='padding-left: 30pt'>
<li>tinea cruris</li>
<li>tinea corporis</li>
</ul>
</p>

<br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>102kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>7.54kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
